Literature DB >> 23475472

Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989-2010).

S Ben-Shimol1, R Dagan, Y Schonmann, N Givon-Lavi, N Keller, C Block, I Kassis, M Ephros, D Greenberg.   

Abstract

AIM: To describe the dynamics in the incidence of childhood invasive meningococcal disease (IMD) in Israel during a 22-year period (1989-2010).
METHODS: A longitudinal prospective surveillance in all 27 medical centers with pediatric services in Israel. All cases of children <15 years old with positive blood/cerebrospinal fluid (CSF) culture for Neisseria meningitidis were reported. Demographic, clinical, and bacteriological data were recorded. Meningococcal vaccine was not routinely given to Israeli children during the study period.
RESULTS: The mean age ± standard deviation (SD) among the 743 cases was 40.7 ± 40.2 months. The mean yearly incidence/100,000 was 2.0 ± 0.8. Age-specific incidences were 8.7 ± 2.8, 2.9 ± 1.5, and 0.8 ± 0.5 for children <1, 1-4, and >4 years old, respectively. The overall incidence decreased significantly from 3.7 in 1989 to 1.5 in 2010. Meningitis constituted 69.2 % of all cases. The most common serogroups were: B (76.9 %), C (10.9 %), Y (8.0 %), and W(135) (2.9 %). 78.6 % of all serogroup B isolates were from children <5 years old (p < 0.01). Serogroup C was found mainly in children ≥5 years old (63.4 %). The case fatality rates (CFRs) for children <1, 1-4, >4 years old, and the total study population were 9.2, 12.3, 7.7, and 9.9 %, respectively. CFRs were higher for children without meningitis (14.9 %) compared to children with meningitis (7.9 %) (p < 0.01).
CONCLUSIONS: Overall, and for serogroups B and W135, childhood IMD rates decreased significantly in Israel during the study period, without routine vaccine usage. The most common serogroup in all age groups was B, which was most prevalent in children <5 years old. No change in the trend of the overall CFR was noted during the study period.

Entities:  

Mesh:

Year:  2013        PMID: 23475472     DOI: 10.1007/s15010-013-0439-6

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  35 in total

1.  Serogroup W135 meningococcal disease in Hajj pilgrims.

Authors:  M K Taha; M Achtman; J M Alonso; B Greenwood; M Ramsay; A Fox; S Gray; E Kaczmarski
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

Review 2.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

Review 3.  Impact of meningococcal C conjugate vaccine in the UK.

Authors:  P Balmer; R Borrow; E Miller
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

Review 4.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 5.  Meningococcal polysaccharide-protein conjugate vaccines.

Authors:  Matthew D Snape; Andrew J Pollard
Journal:  Lancet Infect Dis       Date:  2005-01       Impact factor: 25.071

6.  Hepatitis A disease following the implementation of universal vaccination: who is at risk?

Authors:  Z Mor; S Srur; R Dagan; S Rishpon
Journal:  J Viral Hepat       Date:  2009-08-18       Impact factor: 3.728

Review 7.  Quadrivalent meningococcal conjugate vaccines.

Authors:  David Pace; Andrew J Pollard; Nancy E Messonier
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

8.  Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis.

Authors:  R J Scholten; H A Bijlmer; H A Valkenburg; J Dankert
Journal:  Epidemiol Infect       Date:  1994-02       Impact factor: 2.451

Review 9.  Meningococcal vaccines.

Authors:  Delia Bethell; Andrew J Pollard
Journal:  Expert Rev Vaccines       Date:  2002-06       Impact factor: 5.217

Review 10.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

Authors:  David S Stephens; Brian Greenwood; Petter Brandtzaeg
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

View more
  4 in total

1.  Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.

Authors:  Gary M Ginsberg; Colin Block; Chen Stein-Zamir
Journal:  Int J Public Health       Date:  2016-04-22       Impact factor: 3.380

2.  A cluster of invasive meningococcal disease revealed by the characterization of a novel serogroup B meningococcal clone.

Authors:  L Valinsky; J Jaffe; N Keller; C Block; N Abramson; C Stein-Zamir
Journal:  Epidemiol Infect       Date:  2015-06-26       Impact factor: 4.434

3.  Secular trends in invasive meningococcal disease, Massachusetts, 1988-2011: what happened to invasive disease?

Authors:  A H Peruski; P Kludt; R S Patel; A DeMaria
Journal:  Epidemiol Infect       Date:  2014-12       Impact factor: 4.434

4.  Purpuric rash and fever among hospitalized children aged 0-18 years: Comparison between clinical, laboratory, therapeutic and outcome features of patients with bacterial versus viral etiology.

Authors:  Moran Gawie-Rotman; Guy Hazan; Yariv Fruchtman; Yuval Cavari; Eduard Ling; Isaac Lazar; Eugene Leibovitz
Journal:  Pediatr Neonatol       Date:  2019-02-22       Impact factor: 2.083

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.